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Current research efforts on neurological diseases are focused on identifying novel disease
biomarkers to aid in diagnosis, provide accurate prognostic information and monitor dis-
ease progression. With advances in detection and quantification methods in genomics,
proteomics and metabolomics, saliva has emerged as a good source of samples for
detection of disease biomarkers. Obtaining a sample of saliva offers multiple advantages
over the currently tested biological fluids as it is a non-invasive, painless and simple
procedure that does not require expert training or harbour undesirable side effects for the
patients. Here, we review the existing literature on salivary biomarkers and examine their
validity in diagnosing and monitoring neurodegenerative and neuropsychiatric disorders
such as autism and Alzheimer's, Parkinson's and Huntington's disease. Based on the
available research, amyloid beta peptide, tau protein, lactoferrin, alpha-synuclein, DJ-1
protein, chromogranin A, huntingtin protein, DNA methylation disruptions, and micro-
RNA profiles display a reliable degree of consistency and validity as disease biomarkers.Neurological disorders are a family of diseases affecting both
the central and peripheral nervous system, ranging from
neurodegenerative to neurodevelopmental and psychiatric.
Many of these diseases are multifaceted and there is no
consensus about their actual cause, although many studiesedical Sciences, Univers
Sciences, Rafic Hariri Uni
.M. Ojcius), najwane_said
g Gung University.
ublishing services by Else
s/by-nc-nd/4.0/).suggest the involvement of multiple combined factors [1,2].
One aspect of neurological disorders is neurodegeneration,
which is caused by a progressive loss of certain classes of
neurons that affect either motor skill or memory and cogni-
tion. The degeneration of these neurons is usually due toity of the Pacific, Arthur Dugoni School of Dentistry, 155 Fifth St.,
versity Campus e Hadas, Lebanese University, Beirut, Lebanon.
@yahoo.fr (N. Said Sadier).
vier B.V. This is an open access article under the CC BY-NC-ND
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including excitotoxicity, mitochondrial dysfunction, and
intracellular inclusions or extracellular aggregation of toxic
molecules [3]. Early disease detection is critical in assigning
proper treatment therapy to affected patients [4]. Yet diag-
nosis remains a challenge concerning diseases affecting the
central nervous system (CNS) due to multiple delays in the
diagnostic procedure and treatment initiation, which ulti-
mately diminishes treatment effectiveness. Usually the tests
performed for the diagnosis of neurological conditions are
either blood tests or lumbar puncture. Their invasive nature,
especially for the lumbar puncture, usually results in
discomfort, pain and disagreeable side effects for patients,
which necessitates the search for accurate, more advanced
and less invasive testing methods [5]. Recent investigations
have begun to examine the possible use of urine as a less
invasive source of biomarkers, but have not yet been put into
clinical use pending further assessment [6e9].
Saliva is a physiological fluid composed of mucous and
serous secretions containing mucin, alpha-amylase and
different ions [10]. It fulfils a range of functions including:
digestion of nutrients and protection of teeth and oral tissues;
through enzymatic action, lubrication and antibacterial
properties [11]. Saliva is secreted in themouth by the principal
salivary glands: the sublingual, submandibular and the pa-
rotid, which are under direct parasympathetic innervation of
the cranial nerves VII (glossopharyngeal) and IX (facial). The
facial nerve innervates both the sublingual and submandib-
ular glands through the submandibular ganglion, while the
parotid gland is under glossopharyngeal innervation via the
otic ganglion [12]. Therefore this close relation between the
salivary glands and the nervous system could render these
glands' secretions as a useful pool of biomarkers that repre-
sent various normal and pathological physiologies of the
nervous system [13]. Saliva offers a new and easily accessible
physiological fluid that can be collected in a non-invasive
manner and assessed using different analytical assays [14].
Although many diseases have confirmed salivary biomarkers
[15]; diseases affecting the nervous system have few markersTable 1 Normal physiological and neurotoxic functions of the
functions that are known to be performed by the derivatives o
missing due to lack of information regarding the function of th
sAPPa Ab
Normal physiological
function
Normal physiological
function
- Cell survival
- Synaptogenesis
- Neurogenesis
- Neurite outgrowth
- Learning and memory
- Long term potentiation
- Long term depression
- Suppress Ab generation
- Modulate b-secretase activity
- Regulation of glutamate
receptors
[34,35,325]
- Lipid homeostasis
- Cholesterol regulation
- Lipoprotein anti-oxidant
- Transcription factor
- Neurite outgrowth
- Neural viability
- Memory formation
- Regulation of synaptic
activity
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[328available in saliva which are still being investigated. This
narrative review is concerned with the salivary biomarkers of
the most known neurological diseases i.e. Alzheimer's, Par-
kinson's Huntington's, Amyotrophic lateral sclerosis, Multiple
sclerosis, Autism spectrum disorders and finally neuropsy-
chiatric disorders, to establish a general idea about the ad-
vances made in this field in hopes of providing guidelines for
the development of methods to monitor and assess nervous
system health using salivary biomarkers.Alzheimer's disease
Alzheimer's disease (AD) is a chronic neurodegenerative dis-
order of the CNS. It is mainly manifested by dementia,
confusion and cognitive impairment due to the loss of neu-
rons in the hippocampus, basal forebrain and other cortical
areas of the brain [16e18]. AD etiology can be attributed to two
molecules, the amyloid beta peptide and tau protein. Amyloid
beta peptide is proposed to have normal physiological roles in
memory formation, lipid homeostasis, regulation of neuron
activity and neurite growth [19e24]; on the other hand, tau
protein is a member of the microtubule associated proteins
that maintain proper neuronal structure and intracellular
transport [25e27]. Studies onADpathophysiology suggest that
extracellular accumulation of amyloid beta peptides (Ab) in
amyloid plaques and intracellular tau protein neurofibrillary
tangles are the major factors that contribute to neuron cell
death [28e33]. Based on different research efforts, the cause of
neurodegeneration cannot be attributed to only one of the
aforementioned key players in disease pathophysiology
rather than a combinatory effect of both amyloid beta and tau
protein pathologies on neuronal cell death.
Amyloid beta peptides
Using animal models and neural cell lines, functions of the
soluble APP alpha isoform have been described which
encompass neurogenesis, neurite outgrowth, neuritederivatives of APP processing. The following table lists the
f APP processing. It is worth noting that sAPPb and p3 are
ese two derivatives.
AICD
Neurotoxicity Neurotoxicity
laque generation
eurite damage
xidative stress
alcium influx
ro-inflammatory
ynaptic dysfunction
poptosis
hibition of long term
otentiation
e333]
- Transcription factor
- Pro-apoptotic
- Inactivation and degradation
of Ab
- Trigger of apoptosis
- Cytoskeletal destabilization
- Mitochondrial dysfunction
- Pro-inflammatory
- Increase intracellular calcium
- Up regulation of APP and
BACE
[334,335]
b i om e d i c a l j o u r n a l 4 1 ( 2 0 1 8 ) 6 3e8 7 65guidance, axonal transport, learning, memory formation and
synaptogenesis [34,35] [Table 1]. In non-pathologic conditions,
amyloid precursor protein is cleaved first by a-secretase a
member of the ADAM family followed by a subsequent
cleavage by g-secretase. These two proteases are involved in
the normal processing and recycling of transmembrane am-
yloid precursor protein. Normally, APP processing by a-sec-
retase cuts within the amyloid beta sequence and results in
the formation of three main peptides: soluble APP alpha (s-
APPa), which is released into the extracellular space, and an 83
AA fragment (C-83) embedded in the membrane. C83 is finally
cleaved by g-secretase releasing the p3 peptide and the amy-
loid precursor protein intracellular domain (AICD) [36,37]
[Table 1] [Fig. 1].
In AD, a-secretase is substituted by b-secretase known as
BACE-1 which does not cleave APP within the beta amyloid
structure, thus maintaining its integrity and function. This
altered sequence in enzymatic cleavage results in the pro-
duction of (i) a soluble amyloid precursor protein beta (s-APPb),
and (ii) a 99 AA fragment (C-99) that is subsequently cleaved by
g-secretase to produce a 38e43 amino acid residue amyloid-b
peptideand the intracellularAICDdomain [38,39]. Theamyloid
beta 42 (Ab42) isoform which is known to be more amyloido-
genic and neurotoxic than the other isoforms, accumulates
into plaques causing adverse cytopathic effects [40e42]. This
cleavage can also produce the Ab40 isoform, which has been
found to enhance and stabilize Ab42 oligomer. The synergisticFig. 1 The normal and AD pathogenic pathway of APP
processing into its multiple derivatives. In a healthy
individual the primary processing of APP by a-secretase
within the Ab sequence produces the s-APPa which is
released to the extracellular domain. This cleavage of the Ab
domain inactivates its amyloidogenic potential. The
cleavage of the produced C-83 peptide by g-secretase
produces the P3 peptide which is released to the
extracellular space and the AICD which remains inside the
cell. The difference between the normal APP processing
pathway and that of AD is the initial cleavage of APP by b-
secretase in AD, producing an s-APPb and conserving the Ab
sequence. Ab is then released after C-99 processing by g-
secretase. Once secreted to the extracellular space, Ab is free
to aggregate and form amyloid plaques.effects of the two Ab isoforms instigate severe neurite damage
along with neuronal toxicity [43e46] [Fig. 1] [Table 1].
Applying the enzyme-linked immunosorbent assay (ELISA)
to saliva samples, Bermejo Pareja et al. [47] compared amyloid
beta 40 and 42 levels between AD patients and two sets of con-
trols: healthy controls and Parkinson patients. It was evident
that Ab42 levels increased in patients suffering from mild and
moderate AD, but Ab42 levels were comparable to the healthy
controls in severe AD. This reported variation in Ab42 concen-
trations with disease progression, mimics previously estab-
lished CSF findings [48e50]. Ab40 levels remained unchanged
using this technique for all participants. A single study reported
the detection of Ab42 as a urinary biomarker for both AD diag-
nosis and monitoring, with patients suffering from severe de-
mentia exhibiting a complete absence of Ab42 [9].
In contrast to these findings, Kim et al. [51] used antibody-
basedmagnetic nanoparticle immunoassay to show that Ab42
secretion increases with disease progression from mild
cognitive impairment to severe AD; an increase not evidenced
in CSF, but in the brain as deposition of intracerebral Ab42 in
amyloid plaques [49]. Ab40 levels also exhibited an increasing
trend similar to that of Ab42 as opposed to being unchanged in
the previous study but remained without statistical signifi-
cance. Kim et al. have also conducted an ELISA on the saliva
samples and the results were in accordance with their find-
ings using the immunoassay. There exist two scenarios that
might explain the variability of Ab42 concentration between
the two studies. The first being that, excessive loss of intra-
cerebral neurons in advanced AD contributes to the decrease
of released Ab42 which explains the results obtained by
Bermejo-Pareja et al. [47] The second being that, AD induced
reduction in submandibular salivary flow might contribute to
the increase of concentration of Ab42 due to decreased sample
volume which explains the results obtained by Kim et al.
[47,51]. Yet there is still no consensus or precise explanation
for the observed contradiction.
Recent work performed by Lee et al. [52] proved that stabi-
lizing salivary levels of Ab42 peptides by adding thioflavin S to
prevent its aggregation, and inhibiting bacterial growth by
using sodium azide greatly enhanced the results obtained by
ELISA. These compounds act as preservatives and prevent
sample degradation and thus enhance sample quality and
Ab42detection.Ab42detectionbyusing thismethodaccurately
differentiated between controls and individuals at risk or
affected by AD. The concentration of Ab42 in healthy controls
was around 20 pg/ml and in individuals affected by or at risk of
developing ADwas above 40 pg/ml. Lee et al. did not report any
differences in Ab42 concentrations for different disease stages
(mild-moderate-severe) nor did they attempt the detection of
Ab40 with their method. To test the efficiency of the methods
used by Bermejo Pareja et al., Lee et al. performed an ELISA
using the same Invitrogen kit used by Bermejo Pareja et al. and
found that it was only capable of detecting 25% of Ab42 in the
sample when compared to their method.
Using Parkinson patients as controls is essential to prove
the validity and exclusive nature of this diagnostic tool in
identifying amyloid beta exclusively in AD patients. Results
had shown that controls suffering from Parkinson's disease
studied by both Bermejo Pareja et al. and Lee et al. showed no
differences in Ab42 concentrations in comparison to healthy
b i om e d i c a l j o u r n a l 4 1 ( 2 0 1 8 ) 6 3e8 766controls and thus proving the specificity of salivary Ab42 as a
salivary biomarker for AD patients. This comes as sound evi-
dence with the findings of amyloid beta pathology in PD pa-
tients [53e55].
Molecular findings have shown that multiple genes have
been identified as key players in AD diagnosis and prognosis.
The four main genetic mutations in AD target PSEN1, PSEN2,
ADAM10 and APOE. PSEN1 and PSEN2 are both subunits of the
g-secretase complex and have been associated with the fa-
milial cases of AD [56]. ADAM10 is an a-secretase and APOE4 is
a member of the apolipoprotein family which plays a role in
lipid metabolism and is speculated to intervene in amyloid
beta plaque formation. Both ADAM 10 and APOE4 mutations
have been associated with late onset AD [57e59].
Lee et al. [52] reported three non-AD subjects who showed
Ab42 concentrations higher than other controls two of whom
had an extensive family history of AD and one with a PSEN1
mutation. Complimentary findings were provided by Bermejo
Pareja et al. [47] who reported that Ab42 concentrations in the
saliva of AD are independent of APOE4 genotype which is
linked to late onset AD. Given the above presented data about
the implication of PSEN1 mutations in familial AD, it could be
concluded that salivary Ab42 is probably more reflective of
familial AD genotype rather than sporadic AD.
Ab40 concentrations did not show an identical uniform
variation between the two stated studies. Ab40 levels showed
no change between the saliva of patients and of controls with
the ELISA as shown by Lee et al. [52] and Bermejo-Pareja et al.
[47]. On the other hand Ab40 levels followed an increasing
pattern in AD patient saliva that did not reach significance as
demonstrated by Kim et al. [51] using the immunoassay.
Tau protein
Tau protein, known as the Microtubule Associated Protein T
(MAPT), is a member of the microtubule associated protein
family which plays a role in microtubule stabilization and
flexibility by binding to tubulin [26,27]. Normally, tau phos-
phorylation promotes its disassembly from microtubules and
initiates its destabilization and elimination [25,60]. Mutations
in the tau protein sequence altering its phosphorylation site
have been reported to induce tau hyper phosphorylation [61].
Phosphorylated tau (p-tau) can aggregate and form intracel-
lularneurofibrillary tanglesandworksynergisticallywithAb to
enhance its cytotoxic functions [28,61,62]. Following Mass
Spectrometry analysis of patient saliva, Min Shi et al. [13] were
the only groupwho examinedp-tau as a salivary biomarker for
AD. Analysis of tau protein species, which are the phosphory-
lated tau (p-tau) and the total tau (t-tau), conveyed that the
ratio p-tau/t-tau per individual exhibited a significant increase
in affected individuals as compared to healthy controls. This
indicates that the increase of phosphorylated tau with respect
to the total tau concentration could be used as a potential
biomarker for assessment of AD status. It is worth noting that
bothCSFp-tauand t-tauexhibit an increase inADpatients [63].
Acetylcholinesterase activity
Acetylcholinesterase inhibitors (AChE-I) are the primary medi-
cations for AD symptom management and disease control[64,65]. Acetylcholinesterase is the enzyme required to degrade
Acetylcholine (AChE) neurotransmitter released into the syn-
aptic cleft to halt its postsynaptic effects. TheNucleus Basalis of
Meynert is a major cholinergic nucleus of the basal forebrain
which is a principal target of neurodegeneration in AD [66].
AChEhasbeendemonstrated to accumulate inamyloidplaques
and neurofibrillary tangles of AD brains; furthermore many
findings have implicated AChE in Ab pathology and enhancing
neurotoxicity [67e69]. Assessment of AChE catalytic activity in
ADpatientsbyconventionalmethodssuchaspositronemission
tomography showeda significant decrease in this activity in the
affected brain regions [70,71]. Sayer et al. [72] were the first to
report AChE salivary activity by using the Ellman colorimetric
method. They reported that, AChE activity decreases with age
among healthy individuals, and was significantly decreased in
patients with AD who did not respond to AChE-I treatment.
While thosewho respond toAChE-I treatment didnot showany
variation when compared to controls.
Further studies conducted by Bakhtiari et al. [73] and Boston
et al. [74] also using the Ellman colorimetric method, found a
decreasing trend in AChE catalytic activity in AD patients as
compared to controls but these results did not reach signifi-
cance. They both attributed the decrease in catalytic activity
observed by Sayer et al. to long term adaptive changes in the
productionofAChEbecauseof theadministeredADmedication.
Lactoferrin
Current research continues to supply evidence implicating the
immune system as a major player in the course of AD [75,76].
Recent work presented by Carro et al. names lactoferrin as an
impressive new candidate to be one of the first salivary bio-
markers forADearlydetectionanddiagnosis [77]. Lactoferrin is
an antimicrobial peptidewhich targets bacteria, viruses, fungi,
yeasts and protozoa with a known Ab-binding ability. It func-
tions in the modulation of immune reactions and inflamma-
tion [78e87]. The fact that there exists concomitant evidence
implicating systemic and brain infections with AD [88e91],
further emphasizes the validity of lactoferrin as a probable
biomarker for AD. Using Mass spectrometry and ELISA, Carro
et al. [77] demonstrated that salivary lactoferrin concentration
was significantly reduced in AD patients when compared to
healthy controls, and controls suffering from PD. They were
also able to prove the value of lactoferrin in early disease
detection as an early disease biomarker. 14 out of 18 controls
who presented with reduced salivary lactoferrin concentra-
tions comparable to AD associated concentrations developed
either mild cognitive impairment or AD over the course of the
study; while, none of the controls who presented with normal
or high lactoferrin salivary concentrations developedany form
of cognitive impairment. Finally, to establish thevalidityof this
marker and prove that it is truly representative of AD pathol-
ogy, significant correlations were established between lacto-
ferrin levels in salivaandAPOE4allele status,MiniMental State
Examination (MMSE) score, CSF Ab42 and CSF total tau.
Protein carbonyl levels
There is much evidence concerning oxidative stress being
implicated in AD, with reports indicating a wide array of
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lipid peroxidation, DNA, RNA and protein oxidation [92]. Pro-
tein carbonyls originate from protein oxidation. In the process
of carbonylation of proteins, carbonyl side chains are added to
proteins as they undergo oxidation reactions [93]. Protein
carbonyls were found to be elevated in multiple brain regions
in AD subjects such as the hippocampus, parahippocampal
gyrus, inferior parietal lobule, superior and middle temporal
gyri [94,95].
Haixiang Su et al. [96] were able to quantify protein
carbonyl levels by ELISA in saliva samples of AD patients and
found that there is no significant difference between AD and
controls, though they were able to identify a diurnal variation
in carbonyl levels that peak at 2 pm. This intriguing peak was
maintained in both AD patients and control, with dampened
level in APOE 4 genotype patients but this dampening
remained non-significant.Parkinson's disease
Parkinson disease (PD) is a progressive neurodegenerative
disorder resulting in multiple motor and cognitive deficits.
The symptoms of this disorder have been classified into two
groups, motor and non-motor [97] [98]. In most cases the
specific cause of PD remains unknown and the disease has
been termed idiopathic; although, familial forms and envi-
ronmental risk factors have been identified [99,100]. PD
mainly causes loss of two classes of neurons across the brain:
the dopaminergic and the serotoninergic. This neuron loss
triggered by the aggregation of alpha-synuclein proteins
within neurons in structures known as Lewy bodies, the
hallmark of PD, leads to the multiple motor and non-motor
deficits associated with Parkinson [101e103]. PD is classified
into three main types based on the dominant symptom:
tremor dominant type, akinetic-rigid dominant type and the
mixed type [104].
Alpha-synuclein
Alpha-synuclein (a-syn) is a 140 amino acid protein and
member of the synuclein family. It is abundant and ubiqui-
tously found in multiple brain regions such as the striatum,
hippocampus, olfactory bulb, neocortex, thalamus and cere-
bellum [105]. It is located in the presynaptic terminals of
neurons and has shown affinity for SNARE complex proteins
such as synaptobrevin-2, synapsin III and rab3A. a-syn has
been found to affect synapsin III expression and its cellular
distribution in dopaminergic neurons, the caudate and puta-
men of PD patients [106e109]. This results in shifts in neuro-
transmitter vesicle cluster arrangement and dopamine
release. Alpha-synuclein is known to exist in and cycle be-
tween two forms: (i) the soluble cytosolic form which has no
known function [110], and (ii) the membrane bound helical
form which functions in membrane fusion in the cascade of
synaptic events [111]. Alpha-synuclein pathology in familial
PD has been linked to its increased concentrations in neurons,
which can be attributed to increased a-syn gene (SNCA)
expression due to promoter polymorphisms as well as gene
copy number duplication and triplication [112e115]. Alongwith gene overexpression, three point mutations in the SNCA
gene sequence have been identified in familial PD that affect
a-syn aggregation [116e121]. There are two forms of a-syn
aggregation in PD: (i) oligomeric amorphous aggregates which
are linked to multiple organelle dysfunctions as well as de-
fects in the axonal transport system [122e130], and (ii) fibrillar
insoluble aggregates that contribute to the formation of Lewy
Body pathology [131e133].
In the quest to establish a-syn as a prominent salivary
biomarker of PD diagnosis, Devic et al. [134] used western
blotting and spectrometry to establish the presence of a-syn in
human saliva. Using Luminex assay they showed that a-syn
concentrations significantly decrease in the saliva of PD pa-
tients as compared to healthy controls. These findings were
replicated by Al-Nimer et al. [135] and validated by ELISA
assay. Vivacqua et al. [136] were able to measure, using ELISA,
the concentrations of a-syn oligomer (a-synolig) and total
a-syn (syntotal) which is constituted of a-synmonomers and to
a lesser degree a-syn oligomers in saliva. They detected a
significant increase in a-synolig and a-syn olig/a-syntotal ratio in
the saliva of PD patients as compared to healthy controls,
while a-syntotal exhibited a significant decrease in concen-
tration in saliva of PD patients when compared to healthy
controls. These results observed in saliva are mirrored in CSF
[63]. Vivacqua et al. suggested that the difference in concen-
trations between a-syntotal and a-synolig was due to the olig-
omerization of free monomeric a-syn in saliva, which lead to
the reduction of the recorded a-syntotal concentration.
Upon analysis of the results presented byVivacqua et al. for
a-syntotal salivary levels, it was evident that a-syntotal is perti-
nent in more than simply identifying PD patients when
compared to controls, as its levels on a smaller scalewithin the
PD population exhibited correlations with disease severity,
progression, stages and cognitive impairments. a-syntotal was
shown to positively correlate with H&Y scores, MDS-UPDRS
total score and LEDD scores. Indicating that it can provide a
tool for prediction of disease progression as lower concentra-
tions reflect early disease stages, while higher concentrations
reflect late disease stages. Negative correlations were estab-
lished between a-syntotal and both FAB and MOCA scores,
indicating reduced cognitive abilities in PD patients. The in-
crease in a-syntotal with the advancement of disease, was
attributed by Vivacqua et al. to disease progression causing
advanced synaptic and cellular damage that result in a-syn
monomer release into the extracellular medium. Unlike a-syn
total, a-syn olig was not demonstrated to have any correlation
with disease stages and progression. A urinalysis study con-
ducted onaKorean sampledemonstrated that a-syn cannot be
detected in urine of PD patients and healthy individuals.
DJ-1
DJ-1 is a 189 Amino Acid protein; its mutation has been
associated with rare early onset familial autosomal recessive
PD. DJ-1 is speculated to be a pleiotropic neuro-protective
protein that functions as an antioxidant and against mito-
chondrial dysfunction [137e141]. Normally DJ-1 is located
mainly in the cytoplasm and to a lesser extent in mitochon-
dria and nuclei of dopaminergic neurons. Under oxidative
stress DJ-1 monomers dimerize and favour mitochondrial
b i om e d i c a l j o u r n a l 4 1 ( 2 0 1 8 ) 6 3e8 768localization to finally translocate to the cell nucleus. Recent
evidence suggests that DJ-1 recruitment to plasmamembrane
and mitochondria is efficient in neuro-protection only when
cells are under low to moderate oxidative stress [142]. In the
face of oxidative stress, DJ-1 has been shown to have the
ability to reduce hydrogen peroxide species, stabilize Nrf2
transcription factor which regulates the expression of anti-
oxidant proteins and reduce oxidative stress sustained by
neurons upon calciumentry via L-type channels in pacemaker
potentials [138,142,143]. DJ-1 also plays a role in preventing
mitochondrial dysfunction through regulation of SLC25A14
and SLC25A27 which are mitochondrial uncoupling proteins
in dopaminergic neurons of the substantia nigra pars com-
pacta [142]. DJ-1 interacts with PINK1 which is a serine thre-
onine kinase that protects cells from stress induced
mitochondrial dysfunction [139,141]. There is evidence that
implicates DJ-1 in regulation of astrocyte inflammatory re-
sponses as well as astrocytic and neuronal lipid rafts forma-
tion [144,145]. Finally, DJ-1 plays the role of a molecular
chaperone to inhibit the formation of a-synuclein fibrils, an
essential step in the formation of a-syn oligomers which
constitute a key part in PD pathology [146]. Devic et al. [134]
examined DJ-1 concentrations in saliva of PD patients and
their respective healthy controls by Luminex assay and
showed that DJ-1 levels did not correlate with clinical test
scores for the UPDRS motor test, yet have a tendency to in-
crease in PD patient saliva as compared to controls. Using the
same technique, Kang et al. [147] were able to identify a sig-
nificant increase in DJ-1 concentration in patients who are
classified as PD stage 4 according to the H&Y score as
compared to those who were classified as stages 1e3. A sig-
nificant decrease in DJ-1 concentration was realized in pa-
tients with mixed type PD as compared to tremor dominant
and akinetic-rigid dominant type suggesting different mech-
anisms of disease progression in different disease subtypes.
Kang et al. reported no correlation between DJ-1 salivary
concentration and UPDRS scores in accordance with the
findings of Devic et al. In a recent study conducted by Masters
et al. [148] and by performing quantitative immunoblotting,
DJ-1 showed a significant increase in concentration and a
positive correlation with UPDRS motor score and thus reflects
motor disability. In turn, total salivary protein concentrations
were significantly elevated in saliva of patients with respect to
controls and differentiated between them. This elevation was
attributed to autonomic dysfunction in PD patients. After
adjusting DJ-1 levels with respect to total protein concentra-
tion, there was no difference between PD patients and con-
trols. Similar to these studies, results concerning DJ-1
concentrations in CSF remain inconclusive [63]. A urinalysis
study conducted on a Korean sample has shown that DJ-1
concentrations significantly increase in the urine of PD
affectedmaleswhen compared to non-PDmales,while results
for females remained insignificant [8].
Acetylcholinesterase activity
Dopaminergic neuron loss in PD is accompanied by a hetero-
geneous loss of cholinergic neurons affecting various brain
regions. Cholinergic deficit with cholinergic neuron terminal
reduction has been recorded in PD patients, beingmore severewith patients affected by PD associated dementia [149e151]. It
has been established that, the decrease in gait speed associ-
ated with PD is attributed to cholinergic degeneration [152].
Recently, AChE inhibitors were shown to be effective in alle-
viating some PD symptoms [153]. Fedorova et al. [154] ana-
lysed AChE in saliva samples obtained from PD affected
individuals and their relative controls. They were able to un-
cover an increase in enzymatic activity in the saliva of PD
patients when compared to controls. This increase was
representative of disease progression as the increase in AChE
catalytic activity mirrored stage progression in the H&Y score.
Federova et al. analysed total salivary protein concentration
which they found to be significantly increased in PD patient
saliva as a result of hyposiallorhea. The ratio AChE activity/
Total protein concentration was calculated to emphasize that
the increased catalytic activity of AChE can only be attributed
to an alteration in enzymatic function and not enzymatic
concentration. Despite their significant differences, AChE
concentrations and AChE/Total protein ratio displayed an
overlap between controls and PD patients as few patients
presented with values that would classify them as healthy
individuals and vice versa.Huntington's disease
Huntington's disease (HD) is an autosomal dominant neurode-
generativedisorder causedbyanexpansionofN-terminal (CAG)
n trinucleotide repeat of the huntingtin gene (Htt) with locus
4p16.3. Polymorphism in the number of repeats of this trinu-
cleotide is common among the population where repeats
ranging from (CAG)9e36 are considered normal, while repeats
above (CAG)37 are considered pathological [155e157]. The
length of the CAG repeat has been positively correlated with
early disease onset and rate of disease progression [158]. The
altered CAG trinucleotide repeat codes for repeats of glutamine
inthe translated3142AAhuntingtinprotein.Normalhuntingtin
protein contributes to multiple physiological functions
including embryonic development, cell survival, tissue main-
tenance, and cell morphology [159]. In HD, The mutant hun-
tingtin protein is processed by proteases to release the N-
terminal poly-glutamine sequence, these released fragments
can interferewith transcription and trigger neurodegeneration.
Also resulting from this cleavage is the C-terminal sequence of
huntingtin, which mediates cytotoxicity by interfering with
dynamin1 function and endoplasmic reticulum homeostasis
[160]. Mutant huntingtin proteins have been shown to form
cytoplasmicaggregates,whosefunction isstill debated,assome
studies find them as neuroprotective while others advocate
their role in toxicity [161e163]. Neurodegeneration inHDaffects
multiple neuron classes in the neocortex, striatum, cerebellum,
hippocampus, substantia nigra, and brainstem nuclei [164].
Usually, genetic testing for diagnostic confirmation of HD aims
at identifying Htt gene mutations. Here we present Htt protein
as a promising candidate for the diagnosis of HD.
Huntingtin protein
Knowing that testing CSF and blood for Htt protein for diag-
nostic confirmation of HD can be performed, it is still an
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procedure and because of low Htt concentrations in the ac-
quired samples. Blood and CSF Htt protein levels remain fairly
low, with a minimum requirement of a 50 ml blood sample to
successfully detect Htt protein. In addition to variations in Htt
protein concentrations with different blood cell types
[165e167]. In a study conducted by Bloom et al. [168] Htt pro-
tein was successfully detected, using ELISA, in saliva of HD
patients and healthy controls. Therewas a significant increase
in total Htt protein concentration in saliva samples obtained
from HD patients when compared to controls. Additionally,
salivary concentration of mutant Htt was significantly
increased in pre-manifest HD patients when compared to
healthy controls. Thus, salivary Htt can serve as an early
detection biomarker for HD. Given that currently a non-
invasive measure of Htt CNS concentration doesn't exist.
This method could facilitate diagnostic procedures or even
replace existing tests once properly established.Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a motor neuron degen-
erative disorder known to affect men and women in unequal
ratios, approximately 2:1 [169]. The initial presentation of ALS
is muscle weakness followed by progressive paralysis during
the course of the disease, ultimately leading to death. ALS can
also be associated with cognitive manifestations such as
frontotemporal dementia [170,171]. Histologically, cellular in-
clusions are not an uncommon feature of neurodegenerative
diseases as in Alzheimer and Parkinson. As part of its neuro-
pathology ALS has two different types of immunohistochem-
ical inclusions, Bunina bodies, and Ubiquitin-positive TDP-43
inclusions. The exact mode of toxicity employed by these in-
clusion bodies remains unknown, alongwith their contribution
to disease pathology and progression.
ALS usually presents with upper motor neuron degenera-
tion symptoms such as spasticity, hyperreflexia and the
Hoffman sign in combination with lower motor neuron
degeneration symptoms such as fasciculations, muscle
cramps, and muscle atrophy [172]. These manifestations are
mimicked by several other motor neuron degenerative dis-
eases which affect diagnostic efficiency and duration of the
diagnostic period. Familial ALS has been reportedwith genetic
mutations affecting the following genes C9orf72, SOD1, TDP-
43 and FUS/TLS, whereas sporadic ALS has shown mutations
in SOD1, ANG, TDP-43 and TUBA4A genes. These mutations
are rarely tested for, except if there exist a family history of
the disease [173e176]. Because of the strenuous and unspecific
nature of diagnosis, the period between disease onset, proper
diagnosis and treatment initiation is prolonged, and has been
established at 12e14 months [177e179]. Treatment should
begin as early as possible in order to be effective, whichmakes
early diagnosis a crucial and pressing need for ALS patients
[180,181].
Chromogranin A
Chromogranin A (CgA) is a neuroendocrine secretory protein
that is among the constituents of large dense core vesicles ofneurons and endocrine cells containing neuropeptides and
hormones respectively. Normally, CgA performs multiple
physiological functions including regulation of calcium,
vasoconstriction, regulation of glucose metabolism and stor-
age, antimicrobial, antifungal and a major modulator of the
neuroendocrine system [182]. Multiple studies have linked
CgA to pathological features of ALS. For instance, CgA was
shown to interact in a chaperone-like manner with ALS
mutant SOD1 and mediate its secretion, there was a signifi-
cant loss of CgA expressing neurons accompanied by
decreased CgA density in the neuropil and an accumulation of
CgA in the remaining neurons [183e185].
In the study performed by Obayashi et al. [186] using a
YK070 chromogranin A EIA kit, salivary CgA levels were found
to be only significantly elevated in patients with terminal ALS
in comparison with healthy controls, moderate ALS patients
and patients suffering from vascular dementia. Finally, CgA
concentration positively correlated with the El Escorial score
of emotional functioning rather than that of physical mobility,
communication and alimentation. Thus according to these
findings CgA is reflective of disease severity and the affective
state of ALS patients.Multiple sclerosis
Multiple sclerosis (MS) is a neurodegenerative, inflammatory,
demyelinating disorder of the CNS with women being at
higher risk than men (2:1) [187e190]. MS is believed to be an
autoimmune disorder in which lymphocyte T cells target the
myelin sheaths of CNS neurons [191,192]. The destruction of
myelin and the breach in the BBB result in the appearance of
white matter plaques, which are the hallmark of MS. The
main symptoms of the disease can be sensory, motor and
cognitive [193] [194e197] [198]. Psychiatric symptoms do exist
in patients with MS and are manifested commonly by
depression, which is a major cause of mortality in patients by
increasing suicide risk [199e201]. DiagnosingMS usually relies
on clinical examination, MRI scans, evoked potential testing
and analysis of CSF. Because many demyelinating syndromes
mimic MS in its presentation and symptoms, current MS
diagnosis is performed by ruling-out these illnesses based on
multiple tests and differential diagnosis techniques to confirm
a diagnosis with MS [202]. This necessitates the establishment
of easily accessible early diagnostic markers indicative of MS.
Soluble human leukocyte antigen, class II
The Human Leukocyte Antigen (HLA) can be grouped into two
major classes, HLA class I and HLA class II both of which are
coded by the Major Histocompatibility Complex (MHC) gene
cluster and play an important role in antigen presentation and
immune regulation which are key in eliciting an immune
response [203]. Antigen presentation in MS is carried out by
antigen presenting cells (APCs) which include macrophages,
dendritic cells, microglia and astrocytes. These APCs endo-
cytose myelin proteins, process them as autoantigens via the
endolysosomal pathway and the resulting peptides are bound
to MHC class II molecules (i.e. HLA class II). Following antigen
presentation, immune cells are activated and recruited to
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[204e206]. Interestingly, recent evidence has revealed a cor-
relation between HLA mutations and levels of HLA class II
molecules with MS [207e211].
The HLA classes exist in two forms, membrane bound and
soluble. The membrane bound form functions in antigen
presentation while the soluble form is considered as immu-
nomodulatory and has been detected in serum, CSF, sweat,
synovial fluid and saliva. The exact process by which these
soluble HLA are produced or released from the membranes is
still unknown. Some studies suggest that soluble HLA class I
are produced by the liver and play a role in transplant toler-
ance; while, soluble HLA class II remain uncharacterized
[212e215].
In the search for novel diagnostic salivary biomarkers for
MS, Adamashvili et al. [216] determined, using ELISA, that the
concentration of HLA class II is significantly elevated in the
saliva of patients with Relapsing Remitting MS (RRMS)
compared to healthy controls. HLA class I were not detected
by the used technique, even though they are found in low
concentrations in saliva. Adamashvili et al. attributed this to
the low sensitivity of ELISA to low concentrations of soluble
HLA class I. These results conformed to CSF measurements of
both HLA classes. In accordance with Adamashvili, Minagar
et al. [217] reported, using ELISA, an increase in soluble HLA
class II in the saliva of patients suffering from RRMS as
compared to healthy controls and undetectable salivary sol-
uble HLA class I concentrations. They also monitored soluble
HLA class II salivary levels in response to interferon b1-a,
which is a medication commonly used to manage MS. Soluble
HLA class II concentrations exhibited an increase in response
to interferon b1-a treatment with decline in MRI contrast
enhancing lesions and a stable disease course.
Oxidative stress
The release of free radicals such as reactive oxygen or nitro-
gen species (ROS, RNS) is normally performed during an im-
mune response and inflammation. Cells are said to be under
oxidative stress, when the released reactive species over-
whelm their antioxidant defences and cause damage to cell
structures that could ultimately lead to degeneration [218].
With inflammatory and autoimmune reactions being a major
part in MS pathology, oxidative stress is sure to manifest in an
MS affected CNS. In MS, free radicals are generated by acti-
vatedmacrophages, microglia andmitochondrial dysfunction
[219]. Oxidative damage is known to target lipid membranes,
proteins, myelin, macrophages, astrocytes, oligodendrocytes
and inhibit gene expression essential for myelination. ROS
also contribute to the pathological plaque formation in MS
[219e221]. In the quest for establishing saliva as a reliable pool
of oxidative stressmarkers for diseasemonitoring, Karlik et al.
[222] performed four analytical tests on saliva and blood
samples obtained from MS patients. They dosed Advanced
Oxidation Protein Products (AOPP) a marker of protein oxida-
tion, Thiobarbituric Acid Reacting Substances (TBARS) a
marker of lipoperoxidation and finally advanced glycation end
products (AGEs) and fructosamine which are markers of
carbonyl stress. Of the four dosed oxidative stress markers,
TBARS and AGEs were significantly elevated in saliva of MSpatients as compared to healthy controls, while AOPP
remained unchanged. All four of the dosed markers exhibited
a significant increase in plasma. Karlik et al. also assessed
Total Antioxidant Capacity (TAC) and Ferric Ion Reducing
Ability of saliva/plasma (FRAS/P), both of which represent
saliva's and blood's antioxidant power. They found FRAS to be
significantly lower in MS patient saliva samples as compared
to healthy controls, while TAC levels were lower without
reaching significance. The authors attributed this difference
to the fact that FRAS only measures the antioxidative effects
of non-protein molecules, but as the name suggests, TAC
provides a total measure of antioxidative capacity in a certain
fluid and is therefore affected by multiple variables. Mean-
while, plasma TAC levels decreased significantly between MS
patients and controls, and FRAP remained unchanged. With
the exception of one study reporting no change in CSF
oxidative stress markers [223], studies conducted on CSF
revealed that TBARS are increased in CSF of MS patients when
compared to controls, with a decrease in TAC [221,224,225].Autism spectrum disorders
Autism spectrum disorder (ASD) is a neurodevelopmental
disorder presenting with impairments in social communica-
tion, interaction and restricted repetitive patterns of behav-
iour. Autistic disorder, Asperger's disorder, Rett's disorder,
Childhood disintegrative disorder, Pervasive developmental
disorder-Not otherwise specified-are the group of disorders
that make up the ASD [226]. Despite genetic mutations being
linked to the disorder and strong evidence supporting the
genetic roots of ASD, there is no consensus over the specific
etiology of ASD [227e229]. There exists evidence of both
neurodegeneration and neuroinflammation in ASD, man-
ifested by microglial activation, proinflammatory cytokine
release and neuron loss [230,231]. Alterations in the histology
and anatomy of the frontal lobe, amygdala and cerebellum
have been discussed as part of the neuropathology of ASD
with over-all developmental time-course of the brain being
affected [232,233]. Diagnosis of ASD is based on clinical ex-
amination to identify themain symptoms of the disorder. Due
to the genetic polymorphism of ASD, genetic testing is
impractical to establish a diagnosis. Of the existing immuno-
logical, biochemical and hormonal biomarkers in CSF and
blood for ASD, analysing blood serotonin level is the most
established [234,235]. Functional MRI neuroimaging is also
employed to detect differences in neurofunctional and
neurophysiological activity of the ASD brain [235]. Given that
early detection of ASD is important and that usually a diag-
nosis is not established before the age of 2 years [236e239], the
search for new and easily accessible biomarkers is required
that might precede the morphological and physiological
changes of the disorder or help monitor the patients.
Micro-RNAs
With the ongoing search for biomarkers and causes for ASD,
after identification of the genetic diversity of the disorder
[227e229], research has turned to epigenetics. Epigenetics
plays an important role regulating gene products without
Table 2 List of the upregulated salivary proteins obtained from ASD patients and their respective functions.
Protein Length Function References
Prolactin-inducible protein (PIP) 146 AA - IgG binding
- Actin binding
- Aspartic-type endopeptidase activity
- Regulation of T-cell apoptosis
- Regulation of immune system
[336]
Lactoferrin/Lactotransferrin (LTF) 711 AA - Innate Immunity
- Antibacterial
- Antiviral
- Antifungal
- Immune modulator
[78,79,82,85,86]
Ig kappa chain C region
(IGKC)
IgG gamma-1 chain C region
(IGHG1)
107 AA
330 AA
- Constant region of immunoglobulin
heavy chains
- Humoural immune response
Annexin A1 (ANXA1) 346 AA - Anti-inflammatory
- Regulation of immune system
- Wound repair
- Chemotaxis
- Neutrophil extravasation
[337e342]
Neutrophil-defensin 1
(DEFA1/DEFA1B)
94 AA - Chemotaxis
- Antimicrobial immune response
- Gram positive antibacterial
- Innate immune response
[343,344]
Neutrophil elastase
(ELANE)
267 AA - Calcium homeostasis
- Negative regulation of chemotaxis and
inflammation
- Gram negative antibacterial
- Down-regulation of chemokine
production
- Up-regulation of IL-8 production and
MAP kinase activity
- Transcriptional repressor
[345e350]
Lactoperoxidase (LPO) 712 AA - Antibacterial [351]
Lipocalin 1 (LCN1) 176 AA - Cysteine proteinase inhibitor
- Retina homeostasis
[352,353]
Polymeric immunoglobulin receptor
(PIGR)
764 AA - Transepithelial transport of
immunoglobulins
[354e356]
Deleted in malignant brain
tumours 1 protein
(DMBT1)
2413 AA - Carcinogenesis
- Possible tumour suppressor
[357e359]
Myeloperoxidase (MPO) 745 AA - Apoptosis
- Innate immune response
- Inhibits adaptive immune response
- Microbicidal
- Neutrophil recruitment
- Oxidative stress
[360e366]
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(miRNA) are short single stranded RNA sequences that inter-
fere with gene expression by interacting with target mRNA
and regulating its translation into protein. Multiple miRNA
expression profiles have been elucidated in ASD most of
which are involved in nervous system development and
function [240e242]. In efforts to establish new diagnostic
biomarkers for ASD, salivary miRNA profiling was performed
by Hick's et al. [243] who was able to discover 14 differentially
expressed miRNAs in ASD patient saliva when compared to
healthy individuals. From these 14 miRNAs 4 were down-
regulated in saliva samples of ASD patients (miR-23a-3p, miR-
27a-3p, miR-30e-5p and miR-32-5p) and the remaining ten
were upregulated (miR-140-3p, miR2467-5p, miR-218-5p, miR-28-5p, miR-335-3p, miR-628-5p, miR-7-5p, miR-191-5p, miR-
127-3p and miR-3529-3p). All miRNA levels were predictive of
the Vineland Adaptive Behaviour score especially for neuro-
developmental scores except for miR-140-3p. Knowing that
the Vineland Adaptive Behaviour scale is a psychometric
assessment test for psychological and psychiatric disorders
and that a lowVineland score indicates an impairment [244], it
was interesting to find that the upregulated miRNAs nega-
tively correlated with the Vinland score while downregulated
miRNAs positively correlated with the score. Further, inves-
tigation of possible target genes for the identified miRNA
revealed a vast number of enriched neurodevelopment linked
and ASD linked genes. This indicates that creating a miRNA
salivary profile for ASD can help properly diagnose infants
b i om e d i c a l j o u r n a l 4 1 ( 2 0 1 8 ) 6 3e8 772with the disorder before prominent behavioural manifesta-
tions appear.
Salivary proteome
With the immune system suspected to play an important role
in ASD pathology, proteins implicated in immune reactions
are expected to be deregulated. Studies regarding the ASD
related neuroimmune disturbances as well as correlation of
ASD with parental autoimmune disorders further verifies that
the deregulation of the immune system is either etiological or
consequential to ASD [231,245e249]. In the quest of estab-
lishing new ASD salivary biomarkers, Ngounou Wetie et al.
[250] conducted a pilot study in which they examined dis-
crepancies in salivary protein levels and signatures between
ASD patients and healthy controls. By employing Mass
Spectrometry-based proteomics, they were able to identify a
variability in salivary proteomic levels for ASD with 12 pro-
teins having an elevated concentration and 4 proteins with
reduced concentration in ASD patient saliva when compared
to healthy controls. The list of proteins with elevated and
reduced concentrations in saliva of ASD patients along with
their physiological functions are summarized in Tables 2
and 3. It is evident that all the mentioned proteins are
involved in immune reactions. Further analysis of
proteineprotein interactions revealed that LTF and PIP both
interact with prolactin. A similar analysis revealed that sub-
maxillary gland androgen-regulated protein 3B, statherin and
histatin all interact with one another. This observation led
Ngounou Wetie et al. to the conclusion that protein complex
formation might be compromised in ASD. In the same
context, Castagnola et al. conducted a proteomic study aimed
at identifying changes in the post-translational modifications
of salivary proteins. They were able to detect salivary protein
hypophosphorylation for ASD patients when compared to
healthy controls. The four studied hypophosphorylated pro-
teinswere statherin, histatin and proline rich proteins 1 and 3.
These findings support the above data indicating thatTable 3 List of the downregulated salivary proteins obtained fr
Protein Length
Salivary acidic proline rich
phosphoprotein (PRH1/2)
166 AA
Submaxillary gland androgen-regulated
protein 3B (SMR3B)
79 AA
Statherin (STATH) 62 AA
Histatin-1 (HTN1) 57 AAmolecular changes in proteinsmight affect their physiological
functions. Castagnola et al. [251] stated that hypophosphor-
ylation serves more as an explanation for failed protein
mechanisms rather than a biomarker and therefore could
explain the essence of proteineprotein interaction deficits.
We can thus conclude that biochemical and physiological
changes affect salivary proteins in ASD.
Oxytocin
Oxytocin is a neuropeptide produced by the hypothalamus
and secreted by the posterior pituitary. It is known to function
in the brain in neuromodulation, regulating the mother and
infant bond, sexual behaviour and social recognition
[252e254]. Studies have associated oxytocin dysfunction with
multiple aspects of ASD and its administration has been found
to alleviate social impairment symptoms [255e258]. In the
light of the affiliation present between oxytocin and ASD two
studies were performed to dose oxytocin saliva concentra-
tions in ASD patients and compare them with healthy con-
trols. By implementing an ELISA, Feldman et al. [259] proved
that detection of salivary oxytocin was possible during early
disease stages and salivary oxytocin levels in ASD patients to
be significantly lower than those of normal controls. Fujisawa
et al., [260] were able to dose oxytocin in saliva of both healthy
controls andASD patients by an ELISA aswell. Their assaywas
directed at associating oxytocin salivary levels with visual
attention for social signals which resulted in inconclusive
evidence. Finally, a meta-analysis performed by Grazia et al.
[261] combined the data of the two studies obtaining a 152
individual sample and concluded that there is no significant
difference in salivary oxytocin levels between ASD patients
and healthy controls. In addition to saliva, Grazia et al. con-
ducted a meta-analysis on data obtained on oxytocin levels in
serum and CSF which yielded the same results obtained from
the data on saliva. Not enough data was retrieved on urine to
properly conduct a meta-analysis and obtain significant re-
sults [261].om ASD patients and their respective functions.
Function References
- Calcium binding
- Inhibition of calcium phosphate crystal
formation
- Inhibition of calcium carbonate
precipitation
- Maintenance of oral health
[367e370]
- No known function
- Inhibition of calcium phosphate precip-
itation and crystal growth
- Enamel boundary lubricant
- Oral bacteria colonization
[371e374]
- Inhibition of calcium phosphate precip-
itation and crystal growth
- Antifungal
- Wound healing
- Enamel pellicle formation
[375e377]
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Schizophrenia, bipolar disorder and attention deficit hyper-
activity disorder (ADHD) all fall under the title of neuropsy-
chiatric disorders, which present with multiple behavioural
symptoms. Symptoms of schizophrenia are grouped into: (i)
Positive e delusions and hallucinations; (ii) Negative e
reduced motivation, social impairments, reduced pleasure
and blunted affect; and finally (iii) Disorganized speech and
behaviour [262e264]. Bipolar disorder is classified as a major
mood disorder with symptoms of varying degrees of mania
and depression [265]. Aside from the multitude of social im-
pairments that affect patients, a high suicide risk has been
correlated with both schizophrenia and bipolar disorder
[266,267]. Of the three mentioned disorders only ADHD is
classified as a childhood disorder. ADHD is characterized with
severe persistent debilitating hyperactivity that leads to
functional and social impairments [265]. A diagnosis is usually
established for these disorders after proper clinical examina-
tion and observation based on the aforementioned symptoms
and other DSM-V criteria [226]. Genetic causes have been
associated with all three diseases, but the specific etiology
remains to be elucidated [268e273]. Given that diagnosis of the
Neuropsychiatric disorders relies on clinical examination of
the patient without the establishment of specific disease
biomarkers, exploration of physiological fluids for easily
accessible and accurate biomarkers seems essential in efforts
to provide innovative and faster diagnostic processes.DNA Methylation
Multiple genes can be named as players in causing the
aforementioned neuropsychiatric diseases, as there is no
single culprit capable of explaining the various symptoms and
types of the disorders [268e273]. Because of this, research has
turned its attention towards the possible implication of
aberrant epigenetics in causing the pathological phenotypes
associated with neuropsychiatric disorders [274e279]. On this
basis, investigation of methylation profiles of salivary DNA of
schizophrenic, bipolar and ADHD patients allowed the iden-
tification of four genes HTR2A, DTNBP1, MB-COMT and VIPR2
[Table 4] with epigenetic alterations when compared to
normal controls [280e283]. Cumulative research efforts are
providing mounting evidence for the involvement of HTR2A,
DTNBP1 and MB-COMT in both schizophrenia and bipolar
disorder [284,285]. Deregulation of both serotoninergic and
dopaminergic systems have been shown, with these genes
known as major players in their pathways [286e289]. Patho-
logical genetic variants of HTR2A, DTNBP1 and MB-COMT
were proven to affect memory [290e292], hallucinations
[293], glutamate signalling [291], and symptom severity
[294,295]. Reports of correlations between VIPR2 methylation
and ADHD may be premature and thus the function of this
gene in ADHD requires further studies [296,297]. In fact, the
study conducted by Wilmot et al. [283], who detected VIPR2
CpGmethylation in saliva, was the first of its kind performing
a genome wide DNA methylation analysis for ADHD. Aside
from the downregulation of DTNBP1, the study conducted by
Abdolmaleky et al. [280] characterized the level of gene
b i om e d i c a l j o u r n a l 4 1 ( 2 0 1 8 ) 6 3e8 774methylation as an indicator to treatment responsiveness for
both schizophrenic and bipolar subjects. Results indicated
that patients undergoing and responding to treatment had
lower levels of DTNBP1 promoter methylation as compared to
untreated patients. The disease-associated hypermethylation
was detected in early schizophrenic patients and in healthy
first degree relatives, with higher levels of methylation asso-
ciated with early disease onset. This data supports the merit
of DTNBP1 in disease prediction and treatment management.
Similar to DTNBP1, HTR2A hypomethylation was also detec-
ted in first degree relatives, suggesting the heritability of the
epigenetic anomaly [281]. In addition, by comparing salivary
samples to post-mortem brain samples, the salivary methyl-
ation status of MB-COMT, DTNBP1 and HTR2Awas reported to
mirror the brain's methylation status for these genes.
Salivary proteome
Similar to the discussed Neurodegenerative diseases, immune
system deregulations have been put into evidence for bipolar
disorder and schizophrenia [298e301]. Thus it is only logical
that levels of proteins involved in eliciting an immune
response ought to be altered in schizophrenic and bipolar
patients when compared to healthy controls. From this
standpoint, Iavarone et al. [302] conducted a salivary prote-
ome analysis and found eight immune system-related pro-
teins to be elevated in the saliva of schizophrenic and bipolar
patients when compared to healthy controls. The identified
proteins were a-defensins 1e4, S100A12, cystatin A and the S-
derivatives of cystatin B (glutathionylated and cysteinylated).
All were significantly increased in both disorders except for
a-defensin 3 in bipolar disorder, where it exhibited a slight
non-significant decrease with respect to the controls. All of
the mentioned proteins are involved in innate immunity and
therefore indicate an immunologic imbalance in schizo-
phrenic and bipolar patients [303e306].Discussion
Early detection of neuro-degenerative and neuropsychiatric
disorders is imperative for better disease prognosis and the
initiation of early treatment [4]. The two main physiological
fluids that are used for the detection of such markers are CSF
and blood. Acquiring samples of these two fluids has proven
to cause a certain level of discomfort and pain to the patient
[5]; therefore, it is essential to establish a substitute that is less
invasive but remains representative of the body's physiolog-
ical changes. A good candidate offering promise as a
biomarker pool for neurological disease diagnosis and moni-
toring is saliva. It is an easily accessible biological fluid and its
collection is non-invasive, painless and cost effective [14]. In
addition to its ease of collection, saliva is generally safer than
blood and CSF, and its collection does not expose the health-
care provider to needles, thus reducing the risk of pathogen
transmission from patients suffering from chronic infection.
Similar to saliva, urine seems to provide a novel and non-
invasive source of biomarkers for neurological disorders.
Following the genetic findings provided by Lee et al. [52]
and Bermejo Pareja et al. [47], who reported associationsbetween Ab42 concentration in salivawith AD patientmedical
history and genetic data, it could be concluded that salivary
Ab42 is probably more reflective of familial AD genotype
rather than sporadic AD, and can be used as a tool for disease
prediction but requires further investigation. Based on the
differential detection of Ab42 between groups, where it has
been found to be secreted in high concentrations in the saliva
of individuals suffering from or at risk of developing AD, as
compared to healthy controls and controls suffering from PD,
Ab42 can be considered as a prominent candidate as salivary
biomarker for AD; however, a gold standard test must be
developed for its reproducible and accurate detection in
saliva. Further investigation must be carried out in larger
population samples to identify the exact diagnostic concen-
tration ranges for salivary Ab42. Moreover, there is a crucial
need to validate the differential detection of Ab42 in different
disease stages. Unlike Ab42, analysis of Ab40 has produced
conflicting and insignificant findings [47,52]. This lack of evi-
dence renders it less reliable as a salivary biomarker for AD
diagnosis or disease staging without further evaluation.
Similar to Ab42, tau pathology has been reported in Parkin-
son's disease [63]. Therefore, further investigation with
different detection techniques and the inclusion of Parkinson
controls must be performed to confirm the validity and po-
tential use of p-tau/t-tau as a biomarker for AD. As described
by Carro et al. [77], lactoferrin is highly representative of AD
pathophysiology, cognitive impairment and phenotypes and
therefore qualifies as a promising salivary biomarker for dis-
ease diagnosis. Further longitudinal studies and comparative
studies enrolling individuals suffering frommultiple cognitive
impairments are required to establish the true validity and
diagnostic merit of lactoferrin for AD. The weakness of the
study conducted byHaixiang Su et al. [96] on protein carbonyls
as biomarkers for AD lies in the age difference between con-
trols (mean ¼ 69.20) and AD patients (mean ¼ 82.4) which ne-
cessitates a new study with age adjustment among the
compared groups for more accurate findings.
Based on the reports on a-syn and DJ-1 as PD biomarkers
[134e136,147,148], it could be inferred that the two molecular
formsofa-syn,oligomericandmonomeric, canbeconsidered in
the search for salivary biomarkers for PD. With a-syn olig
servingasabiomarker fordiseasediagnosisonly,due to the lack
of data that links it to disease stage and prognosis, and a-syn
total servingasastagingbiomarker to trackdiseaseprogression.
DJ-1 could be considered as a salivary biomarker for diagnosing
the disease and identifying the type of Parkinsonism.
The observations reported on salivary AChE activity in both
AD and PD patients [72e74,154], indicate that at present sali-
vary AChE cannot be used as a diagnostic marker. In light of
present research, AChE could be considered only for moni-
toring disease pathophysiology and parasympathetic dener-
vation in PD. Properly designed andmultifaceted studiesmust
be conducted in order to confirm the potential use of salivary
AChE in AD and PD diagnosis. These studies should take into
account the various disease stages (mild, moderate, and se-
vere) and treatment programs of every patient, as well as the
development of a proper technique for sample collection and
storage for maintaining optimum enzyme function.
Due to their involvement in immune system reactions,
peptides, oxidative stress markers and soluble HLA II
Fig. 2 Summary of salivary biomarkers and their current state of validity. This figure classifies the neurological disorders into
four different types: neurodevelopmental, cognitive, motor and neuropsychiatric disorders. For each one of these disorders, a
categorical system classifies the biomarkers as: promising, inconclusive and negative results based upon the findings of our
work. Abbreviations used: AD: Alzheimer's disease; PD: Parkinson's disease; MS: Multiple Sclerosis; ASD: Autism Spectrum
Disorder; ALS: Amyotrophic Lateral Sclerosis; HD: Huntington's disease; and NPD: Neuropsychiatric Disorders.
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further investigation. It is crucial to conduct comparative
studies between neurological conditions that trigger the
immune system and other immunological conditions, in
order to establish whether these markers are exclusively
indicative of neurological conditions or can be detected in
and affected by the presence of other immunological
deregulations.
Investigations on salivary biomarkers are still inconclu-
sive because there is not enough evidence to support or
negate the actual pertinence of these molecules in saliva.
Most of the existing studies were based on relatively small
samples that lacked sufficient power, in addition to
concluding with few conflicting results. Based on the results
presented by our review, we realize that there are some
biomarkers which are more prominent than others, espe-
cially those proven to be causal for disease phenotypes, while
those associated with other physiological processes like im-
munity and oxidative stress remain somewhat unspecific
unless their presence in saliva is proven to be strictly repre-
sentative of the diseases in question [Fig. 2]. The presence of
the reviewed salivary biomarkers detected in neurological
conditions was also assessed in different commonly tested
physiological fluids: CSF, blood and urine [Table 5], along
with a comparison of each fluid's advantages and disadvan-
tages [Table 6].
That being said, we cannot depend on one biomarker to
ultimately achieve an accurate diagnosis. Instead, a definitive
biomarker profile must be created to be used for future diag-
nostic purposes. The source of these biomarkers remains to be
properly identified. They could be released into saliva from
plasma microfiltration through the gums or expressed insalivary glands. It is also probable that they are transported
directly from the CNS via the axons of the facial and glosso-
pharyngeal nerves to the salivary glands to ultimately be
vacated along with saliva secretion.
Because different fundamental and prominent factorsmay
affect sample quality, saliva collection methods and process-
ing must be refined. In the study conducted by Lee et al.,
stabilizing salivary levels of Ab42 peptides by adding thio-
flavin S to prevent aggregation and using sodium azide to
inhibit bacterial growth, enhanced Ab42 detection in the
sample [52]. Furthermore, the available literature indicates
that patients suffering fromneurological disorders have lower
oral health and are more prone to oral disease than healthy
individuals [307e313]. We thus speculate the possible inter-
ference of reduced oral health and successful biomarker
detection. This raises the question if proper extraction,
handling and treatment of the saliva sample with agents and
compounds known to stabilize the measured molecule will
result in better sample quality and therefore better biomarker
detection.
Another aspect of saliva that might affect proper
biomarker detection is the fact that patients suffering from
some of the neurological diseases listed in this review suffer
from sialorrhea or hyposialorrhea which are excess and
diminished salivation respectively. The changes in saliva
secretion is usually brought on as a side effect of the illness
[314e318] or caused by medication [317,319,320]. This in-
dicates that there is a possibility of shifts in biomarker con-
centrations among healthy controls and patients due to
different secreted concentrations of total salivary proteins.
Consequently, it is recommended to normalise future mea-
surements of salivary biomarkers against total salivary
Table 5 Summary of available reports on the levels of disease biomarkers detected in saliva, CSF, blood and urine and their
respective variations.
Saliva CSF Blood Urine
AD AB42 [ in Moderate AD [47]
Y in Severe AD [47]
[ [51,52]
Y in Severe AD
[48e50,378,379]
[ [380,381]
Y [382,383]
Detected
[9]
AB40 [ [51]
No change [47]
No change [378,379] [ [378,380,384]
Y [385]
N/A
Tau [ [13] [ [63,386,387] No change [384] N/A
Lactoferrin [ [77] N/A No change [388,389] N/A
AChE activity Y [72e74] [ in AD with APOE4 mutation [390]
No change [391]
Y [391]
Y Erythrocyte
AChE activity [392]
No change [391]
N/A
Protein Carbonyls No change [96] No change [393] [ [394e397] N/A
PD a-syntotal Y [136,398]
[ [134,135]
Y [63]
No change [63]
Y [399]
[ [400,401]
Not detected [8]
a-synolig [ [136] [ [63] N/A N/A
a-synolig/a-syntotal [ [136] [ [63] N/A N/A
DJ-1 [ [134,147,148] Y [398]
[ [402,403]
[ [404]
No change [405,406]
[ [8]
AChE activity [ [154] No change [391] [ [407] N/A
HD mHtt protein [ [168] [ [167] [ [165,166] N/A
ALS CgA [ [186] [ [408] N/A N/A
MS s-HLA Class II [ [216] [ [216]
Detected [409]
[ [210]
Y [409]
N/A
TBARS [ [222] [ [221,224,225]
No change [223]
[ [221e224]
No change [225]
N/A
AOPP No change [222] N/A [ [222] N/A
AGEs [ [222] N/A No change [222] N/A
TAC No change [222] Y [221,224] Y [222] N/A
FRA Y [222] N/A No change [222] N/A
Fructosamine N/A N/A [ [222] N/A
ASD Oxytocin No change [261] No change [261] No change [261] N/A
All variations reported are in comparison to healthy controls, Legend: [: increasing, Y: decreasing, N/A: no studies found, Detected: no infor-
mation concerning the concentration only that the biomarker is detected, If biomarker variation is specific to disease stage, phenotype or cell
type, then it is clearly stated.
Table 6 Advantages and disadvantages of sampling saliva, CSF, blood and urine.
Saliva Urine Blood CSF
Advantages - Non-invasive - Highly representative of internal physiology
- Painless
- Cost effective
Disadvantages - Diurnal variation - Moderately invasive - Invasive
- Variable volume - Drowsiness - Pain & Discomfort
- Variable biomarker concentration - Discomfort - Possible allergic reaction to the anaesthetic
- Possible blood contamination - Infection
- Oral healthrowhead - Urinary tract infection - Headache
- Dizziness
- Vomiting
b i om e d i c a l j o u r n a l 4 1 ( 2 0 1 8 ) 6 3e8 776proteins to account for shifts in concentrations of biomarkers
brought about by irregular salivation. Aside from pathological
changes in salivary composition and secretion, it is estab-
lished that there exist circadian rhythms that normally
govern saliva production, composition and flow rate [321].
Thus it is imperative that samples from patients and controls
be collected during the same time frame in order to avoid
normal shifts in saliva protein concentrations from con-
founding the evidence.We propose that future research efforts be directed to-
wards establishing salivary epigenetic signatures based on
micro-RNA analysis. Given that micro-RNA can be success-
fully detected in human saliva [322] and that micro-RNA dis-
ruptions do exist in neurological disease [323,324], it is
possible to create disease specific micro-RNA expression
profiles. These profiles will allow detection of a pathological
fingerprint unique to the disease in question and therefore
allow for a better, more accurate diagnosis.
b i om e d i c a l j o u r n a l 4 1 ( 2 0 1 8 ) 6 3e8 7 77Conclusions
Neurological disorders are generally debilitating for patients
and they impose a socioeconomic burden on these patients
and their caregivers. This highlights the urgent requirement
for the development of easily accessible, non-invasive and
cost effective diagnostic tests that aim at early identification
of neurological diseases. Saliva is a physiological fluid that
shows promise in developing non-invasive testing for disease
biomarkers, but the utility and applicability of salivary bio-
markers in diagnosis of neurological disorders remains in
question. The current research remains inefficient in
discerning the reliability of salivary biomarkers in neurolog-
ical disease detection and monitoring. Due to the lack of data
and conflicting results of the existing studies, there is an
incessant need for increased research efforts to conduct well-
structured clinical trials if a non-invasive screening technique
based on salivary biomarkers is to be realized. Proper saliva
collection and processing protocols must be standardized in
order to decrease biases and allow an accurate identification
of salivary biomarkers. Furthermore, we believe that salivary
biomarkers, in their initial stages, will not be able to solely
detect neurological pathologies, but instead these biomarkers
will serve as means aiding in diagnosis, or simply replacing
other invasive tests. From this standpoint and based on the
reviewed literature, we were able to categorise the available
biomarkers [Fig. 2], in hope of guiding future research en-
deavours along a targeted path to ascertain the validity of the
most promising biomarkers available.Conflicts of interest
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